MRD kinetics after autologous SCT and nonmyeloablative allogeneic SCT. MRD levels (number of CLL-specific DNA copies per total DNA copies in the sample compared with the reference [pretherapeutic] sample) of patients after myeloablative conditioning and auto-SCT (A) and after nonmyeloablative allo-SCT (B). (•) denotes MRD-positive samples; (○) denotes the sensitivity of PCR-negative samples (calculated minimum MRD level, which would have been detected in this particular sample); and (♦) denotes percentage of donor chimerism. (C-F) Individual MRD kinetics in correlation to cyclosporine withdrawal (C), DLI (D), and chronic GVHD (E). (F) Case with discordant MRD and chimerism data, implying that GVL can induce CLL clearance without achieving full donor chimerism.